Advertisement

PentaVision

Retinal Physician

Article

Diagnosing and Managing Polypoidal Choroidal Vasculopathy

Evidence-based strategies for diagnosis and therapeutic decision-making.

By: Giulia Gregori, MD, Jay Chhablani, MD
Retinal Physician March 1, 2026 Vol 23, Issue March-April 2026 Page(s): 6-8

Clinical Scorecard: Diagnosing and Managing Polypoidal Choroidal Vasculopathy

At a Glance

CategoryDetail
Condition
Key MechanismsInvolves choroidal vascular lesions, often considered a variant of age-related macular degeneration (AMD). Genetic and demographic factors play a significant role.
Target Population
Care Setting

Key Highlights

  • PCV is associated with recurrent subretinal hemorrhages and pigment epithelial detachments. Genetic studies indicate involvement of inflammatory pathways and lipid metabolism.
  • Diagnosis is confirmed via indocyanine green angiography (ICGA) and multimodal imaging, including OCT.
  • Treatment options include photodynamic therapy (PDT) and intravitreal anti-VEGF therapy, with consideration of patient demographics.

Guideline-Based Recommendations

Diagnosis

  • PCV diagnosis requires focal hyperfluorescence and at least one additional characteristic finding, including specific imaging results.

Management

  • Treatment options include PDT, intravitreal anti-VEGF therapy, and laser photocoagulation, with emphasis on multimodal imaging.

Monitoring & Follow-up

  • Regular follow-up with multimodal imaging, including OCT, to assess treatment response and disease progression.

Risks

  • Poor response to anti-VEGF therapy may indicate PCV rather than other chorioretinal disorders.

Patient & Prescribing Data

Combination therapies may enhance treatment efficacy in managing PCV, especially in patients with suboptimal responses to conventional treatments.

Clinical Best Practices

  • Utilize multimodal imaging for accurate diagnosis and monitoring, including OCT.
  • Consider genetic and demographic factors in treatment planning.

References